Impacts of Low-Dose Dexmedetomidine on Sleep Quality in Mechanically Ventilated ICU Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 17, 2017

Primary Completion Date

October 31, 2019

Study Completion Date

November 30, 2019

Conditions
AgedPostoperative PeriodIntensive Care UnitsMechanical Ventilation ComplicationSleep DisordersDexmedetomidine
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.

DRUG

Placebo (normal saline)

Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT03335527 - Impacts of Low-Dose Dexmedetomidine on Sleep Quality in Mechanically Ventilated ICU Patients | Biotech Hunter | Biotech Hunter